A new gene therapy that introduced SynCav1 to the brains of Alzheimer's mouse models was shown to preserve neuronal and synaptic plasticity.
List view / Grid view
A novel sensitive label-free imaging method has been developed to visualise brain samples using an FxClear-based tissue clearing technique.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
Oral doses of a new drug named CA administered to mouse models led to improvements in Alzheimer's disease, including memory.
Researchers have developed a stem cell therapy that could treat the damage caused by dementia by launching a repair response.
A study has shown that treatments to reduce levels of hydrogen sulphide (H2S) in the brain may help to prevent dementia.
Researchers have reported that nano-micelles can be used to efficiently deliver CRISPR-Cas9 to edit genes in the brains of mice.
Researchers have shown that an siRNA nanomedicine can target BACE1 in a mouse model of Alzheimer's, restoring cognitive capacity.
A team has shown that inhibiting the soluble epoxide hydrolase (sEH) enzyme in murine models can prevent the cognitive deterioration associated with Alzheimer's.
By administering a one-time PTB antisense oligonucleotide therapy to mice, researchers observed an increase in neurons and elimination of Parkinson's from the models.
Scientists have designed a high affinity antibody for pathogenic amyloid beta oligomers, a key driver of Alzheimer’s disease, for use in further research and as a potential diagnostic tool.
Scientists used optical photothermal spectroscopy (O-PTIR) to image murine neurons affected by early stage Alzheimer’s disease, providing insight into the progression of the disease.
Pre-clinical studies demonstrate that inhibiting the ’epichaperome’ can restore neural networks to normal levels. Dr Barbara Wallner at Samus Therapeutics explains how targeting the epichaperome could work as a potential treatment for Alzheimer’s and other neurodegenerative diseases.
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
Researchers have shown that two epigenetic regulators could be targeted to improve cognitive and behavioural decline in age-related diseases like Alzheimer’s.